Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMED: Mocetinostat and Durvalumab for Oral Cavity Cancer
NCT02993991Phase 1Withdrawn
- Sponsor
- University Health Network
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mocetinostat in squamous cell carcinoma of the oral cavity (OSCC), sponsored by University Health Network. Primary endpoints: Pharmacodynamic effects with biomarker analyses at 3 years and Immune effects with biomarker analyses at 3 years. Planned start Oct 2017; status: withdrawn.
02
Drugs
mocetinostat
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT02993991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993991.